The North America structural heart market is expected to grow from US$ 6,967.50 million in 2022 to US$ 11,201.47 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2022 to 2028.
North America Structural Heart Market Revenue and Forecast to 2028 (US$ Million)
Based on product, the North America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the North America structural heart market in 2022.
Based on procedure, the North America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the North America structural heart market in 2022.
Based on end user, the North America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share of the North America structural heart market in 2022.
Based on country, the North America structural heart market is segmented into US, Canada, and Mexico. US dominated the North America structural heart market in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, and Micro Interventional Devices Inc are some of the leading companies operating in the North America structural heart market.
Availability of Innovative Structural Heart Services Fuel North America Structural Heart Market
According to the World Health Organization (WHO), cardiovascular diseases are the second leading cause of death worldwide. Therefore, various initiatives are being taken to control cardiovascular diseases. Heart valve disease is expected to be one of the most common causes of heart failure. Degenerative diseases of aortic and mitral valves, and diseases of dysfunctional tricuspid valves lead to a worse clinical course in severe cases. Minimally invasive, surgical, and catheter-based interventions for structural heart disease have increased dramatically recently. The structural heart is an evolving field consisting of heart valve surgeries and transcatheter procedures; therefore, various training programs are being arranged for cardiac surgeons and physicians. Over the past decade, the burgeoning incidence of structural heart disease has necessitated the development of formal training programs to ensure the appropriate competency of workforces. The structure, length, and scope of training vary greatly between programs. Most programs provide solid exposure on transcatheter aortic valve replacement (TAVR) procedures, simultaneously providing a lesser and variable experience of atrial septal or ventricular septal defect closure, left atrial appendage closure, and congenital heart defect interventions. With the advent of TAVR, the MitraClip mitral valve repair system (Abbott Vascular), and left atrial appendage occlusion (LAAO) procedures, there has been a significant increase in the volume of structural cardiac procedures performed for treating patients with complex cardiovascular conditions. Many organizations have developed services and procedural offerings in an organized format for the structural cardiac program to accommodate the influx of patients. Training in SHD is exciting, challenging, and rewarding overall. As the field evolves, standardization of SHD training becomes extremely important to ensure the best quality of patient care. Finding a mentor to help navigate the numerous considerations outlined can be the best asset to successfully transitioning from training to practice.North America Structural Heart Market Overview
The North America Structural heart market is estimated to grow at a CAGR of 8.2% from 2022 to 2028. Key factors driving the market growth are innovative structural heart services and rise in the number of cardiovascular diseases and training programs. However, high cost of procedure followed by stringent regulations regarding structure heart device are the major factor hampering the growth of the market.North America Structural Heart Market Revenue and Forecast to 2028 (US$ Million)
North America Structural Heart Market Segmentation
The North America structural heart market is segmented into product, procedure, end user, and country.Based on product, the North America structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. The occluders segment held the largest share of the North America structural heart market in 2022.
Based on procedure, the North America structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. The heart valve stenosis segment held the largest share of the North America structural heart market in 2022.
Based on end user, the North America structural heart market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals segment held the largest share of the North America structural heart market in 2022.
Based on country, the North America structural heart market is segmented into US, Canada, and Mexico. US dominated the North America structural heart market in 2022.
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc, Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomedica Industry, Commerce and Representations Ltd, and Micro Interventional Devices Inc are some of the leading companies operating in the North America structural heart market.
Table of Contents
1. Introduction
3. Research Methodology
4. North America Structural Heart Market - Market Landscape
5. North America Structural Heart Market - Key Market Dynamics
6. North America Structural Heart Market -North America Analysis
7. North America Structural Heart Market - Revenue and Forecast to 2028 - by Product
8. North America Structural Heart Market - Revenue and Forecast to 2028 - by Procedure
9. North America Structural Heart Market - Revenue and Forecast to 2028 - by End User
10. North America Structural Heart Market - Revenue and Forecast to 2028 -Country Analysis
11. North America Structural Heart Market -Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Medtronic Plc
- Boston Scientific Corp
- Artivion Inc
- Edwards Lifesciences Corp
- Lepu Medical Technology Beijing Co Ltd
- Braile Biomedica Industry, Commerce and Representations Ltd
- Micro Interventional Devices Inc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 133 |
Published | October 2023 |
Forecast Period | 2022 - 2028 |
Estimated Market Value in 2022 | 6967.5 Million |
Forecasted Market Value by 2028 | 11201.47 Million |
Compound Annual Growth Rate | 8.2% |
Regions Covered | North America |
No. of Companies Mentioned | 8 |